Article
An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Nature medicine - 1 May 2019
Kopper Oded, de Witte Chris J, Lõhmussaar Kadi, Valle-Inclan Jose Espejo, Hami Nizar, Kester Lennart, Balgobind Anjali Vanita, Korving Jeroen, Proost Natalie, Begthel Harry, van Wijk Lise M, Revilla Sonia Aristín, Theeuwsen Rebecca, van de Ven Marieke, van Roosmalen Markus J, Ponsioen Bas, Ho Victor W H, Neel Benjamin G, Bosse Tjalling, Gaarenstroom Katja N, Vrieling Harry, Vreeswijk Maaike P G, van Diest Paul J, Witteveen Petronella O, Jonges Trudy, Bos Johannes L, van Oudenaarden Alexander, Zweemer Ronald P, Snippert Hugo J G, Kloosterman Wigard P, Clevers Hans
Abstract excerpt
Ovarian cancer (OC) is a heterogeneous disease usually diagnosed at a late stage. Experimental in vitro models that faithfully capture the hallmarks and tumor heterogeneity of OC are limited and hard to establish. We present a protocol that enables efficient derivation and long-term expansion of OC organoids. Utilizing this protocol, we have established 56 organoid lines from 32 patients, representing all main...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.